Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Ibrahim Y Abdelgawad"'
Publikováno v:
PLoS ONE, Vol 15, Iss 7, p e0232507 (2020)
Sex-related differences in cardiovascular diseases are highly complex in humans and model-dependent in experimental laboratory animals. The objective of this work was to comprehensively investigate key sex differences in the response to acute and pro
Externí odkaz:
https://doaj.org/article/9c389607ccce4c54a0d1e546329b3138
Autor:
Marianne K O Grant, Davis M Seelig, Leslie C Sharkey, Wan S V Choi, Ibrahim Y Abdelgawad, Beshay N Zordoky
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212486 (2019)
Doxorubicin (DOX) is a chemotherapeutic agent that has been reported to cause nephrotoxicity in rodent models and to a lesser degree in cancer patients. Female rodents have been shown to be protected against several features of DOX-induced nephrotoxi
Externí odkaz:
https://doaj.org/article/f01a23fc57b54b2789b1131bf632ea8b
Autor:
Ibrahim Y. Abdelgawad, Kevin Agostinucci, Bushra Sadaf, Marianne K. O. Grant, Beshay N. Zordoky
Publikováno v:
Frontiers in Aging, Vol 4 (2023)
Introduction: Doxorubicin (DOX), a chemotherapeutic drug, induces senescence and increases the secretion of senescence-associated secretory phenotype (SASP) in endothelial cells (ECs), which contributes to DOX-induced inflammaging. Metformin, an anti
Externí odkaz:
https://doaj.org/article/3e9bb987275342a98f7502970525dca0
Autor:
Marianne K. O. Grant, Maria Razzoli, Ibrahim Y. Abdelgawad, Rachel Mansk, Davis Seelig, Alessandro Bartolomucci, Beshay N. Zordoky
Publikováno v:
Stress, Vol 25, Iss 1, Pp 291-304 (2022)
Childhood cancer survivors have a high risk for premature cardiovascular diseases, mainly due to cardiotoxic cancer treatments such as doxorubicin (DOX). Psychosocial stress is a significant cardiovascular risk factor and an enormous burden in childh
Externí odkaz:
https://doaj.org/article/937f9516f6584ce1aeb6dbce0b53c2c6
Autor:
Ibrahim Y. Abdelgawad, Kevin Agostinucci, Somia G. Ismail, Marianne K. O. Grant, Beshay N. Zordoky
Publikováno v:
Cells, Vol 11, Iss 13, p 1992 (2022)
Doxorubicin (DOX) induces endothelial cell (EC) senescence, which contributes to endothelial dysfunction and cardiovascular complications. Senolytic drugs selectively eliminate senescent cells to ameliorate senescence-mediated pathologies. Previous s
Externí odkaz:
https://doaj.org/article/8c9b283b40fb4b2a85518d987dde1ea5
Autor:
Mohamed S. Dabour, Ibrahim Y. Abdelgawad, Marianne K.O. Grant, Engie S. El-Sawaf, Beshay N. Zordoky
Publikováno v:
Biomedicine & Pharmacotherapy. 164:114907
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a13f812e53c5c27c303ca80008a9da5d
https://doi.org/10.1016/j.biopha.2023.114907
https://doi.org/10.1016/j.biopha.2023.114907
Autor:
Kevin Agostinucci, Marianne K. O. Grant, Wongel Melaku, Ibrahim Y. Abdelgawad, Beshay N. Zordoky
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbc4f34427c08add354502dd2a623541
https://doi.org/10.1096/fasebj.2022.36.s1.r2643
https://doi.org/10.1096/fasebj.2022.36.s1.r2643
Publikováno v:
Biochim Biophys Acta Mol Basis Dis
Cancer survivorship has remarkably improved over the past decades; nevertheless, cancer survivors are burdened with multiple health complications primarily caused by their cancer therapy. Therapy-induced senescence is recognized as a fundamental mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df43bea36133cb95236fd3c272793bf2
https://europepmc.org/articles/PMC8844223/
https://europepmc.org/articles/PMC8844223/
Publikováno v:
The FASEB Journal. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6d9c6ada285c9fb8b03274f491b8b61
https://doi.org/10.1096/fasebj.2021.35.s1.02786
https://doi.org/10.1096/fasebj.2021.35.s1.02786
Autor:
Ibrahim Y. Abdelgawad, Ahmed A. Suleiman, Brenda Chyla, Majd Ghanim, Ahmed H. Salem, Mohamed Badawi
Publikováno v:
Cancer Research. 82:1257-1257
The approval of targeted therapies has greatly improved outcomes for patients (pts) with chronic lymphocytic leukemia (CLL) in both 1L and relapsed/refractory (R/R) settings. The use of long-term outcomes such as progression free survival (PFS) and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e58148c0fc28a2eaa2c28c2fa786f2e0
https://doi.org/10.1158/1538-7445.am2022-1257
https://doi.org/10.1158/1538-7445.am2022-1257